Mesenchymal stem cell-derived exosome mitigates colitis <i>via</i> the modulation of the gut metagenomics–metabolomics–farnesoid X receptor axis-Reference-Cited by-同舟云学术

Mesenchymal stem cell-derived exosome mitigates colitis via the modulation of the gut metagenomics–metabolomics–farnesoid X receptor axis

Published:2022 Issue:17 Volume:10 Page:4822-4836
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Ocansey Dickson Kofi Wiredu¹²,Zhang Zhiyu³,Xu Xinwei¹,Liu Lianqin¹,Amoah Samuel²,Chen Xiang⁴,Wang Bo¹,Zhang Xu¹,Mao Fei¹^ORCID

Affiliation:

1. Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang 212013, Jiangsu, P.R. China

2. Directorate of University Health Services, University of Cape Coast, PMB, Cape Coast, Ghana

3. The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Zhenjiang 212300, Jiangsu, P.R. China

4. Zhenjiang Institute for Drug and Food Control, Zhenjiang 212001, Jiangsu, P.R. China

Abstract

IBD is associated with chronic gut immune dysregulation and altered microbiome and metabolite composition. MSC-Ex mitigates DSS-induced IBD in mice by modulating the gut metagenomics–metabolomics–FXR axis.

Funder

Jiangsu Commission of Health

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2022/BM/D2BM00559J

Reference50 articles.

1. Inflammatory bowel disease

2. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease

3. Gut microbiota in the pathogenesis of inflammatory bowel disease